141
Participants
Start Date
January 27, 2021
Primary Completion Date
November 9, 2023
Study Completion Date
November 27, 2024
Inclisiran
Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL solution for subcutaneous injection
Placebo
Sterile normal saline (0.9% sodium chloride in water for subcutaneous injection)
University Medical Centre Ljubljana, Div. of Pediatric Dept. of Endocrinology, Diabetes and Metabolic Diseases, Ljubljana
Novartis Investigative Site, Geneva
Novartis Investigative Site, Somerset West
Novartis Investigative Site, Pécs
Novartis Investigative Site, Cape Town
Novartis Investigative Site, Bloemfontein
Icahn School of Medicine at Mount Sinai, New York
Taipei Veterans General Hospital, Taipei
Novartis Investigative Site, Prague
Hospital Reina Sofia, Córdoba
Hospital Abente y Lago, A Coruña
Childrens Hospital Pittsburgh of UPMC, Pittsburgh
Metropolitan Hospital, Athens
Novartis Investigative Site, Milan
Far Eastern Memorial Hospital, New Taipei City
Novartis Investigative Site, Irbid
Novartis Investigative Site, Besançon
Wake Forest U of Health Sciences, Winston-Salem
Hospital Virgen de la Vcitoria, Málaga
Novartis Investigative Site, Pamplona
Novartis Investigative Site, Toulouse
Hospital Central de Asturias, Oviedo
Novartis Investigative Site, Istanbul
Novartis Investigative Site, Izmir
Novartis Investigative Site, Modena
UiTM Sungai Buloh, Sungai Buloh
Lipids Center Sheba Medical Center, Israel, Ramat Gan
KKIM UK Frankfurt/Main, Frankfurt
Universitaetsmedizin Mannheim, Mannheim
Novartis Investigative Site, Bron
Universitaetsklinikum Freiburg, Freiburg im Breisgau
Primary Children's Medical Center, Salt Lake City
Tucson Medical Center, Tucson
Novartis Investigative Site, Moscow
Hotel Dieu de France Hospital, El Achrafiyé
Institute of Internal Prev. Med., Novosibirsk
Institute of the complex problems of cardiovascular disease, Kemerovo
Lipid Research, Jerusalem
Unidade de pesquisa clinica - Hospital Universitario Walter Cantidio, Fortaleza
Cincinnati Children's Hospital Medical Center, Cincinnati
Novartis Investigative Site, Formosa
Nucleo de Pesquisa Clinica do Rio Grande do Sul, Porto Alegre
Setor de Lípides, Aterosclerose e Biologia, São Paulo
Heart Institute (InCOr) HCMFUSP, São Paulo
Novartis Investigative Site, Québec
Novartis Investigative Site, Prague
University General Hospital of Ioannina, Ioannina
Hippokrateion General Hospital of Athens Greece, Athens
Novartis Investigative Site, Roma
Novartis Investigative Site, Roma
Novartis Investigative Site, Rotterdam
Novartis Investigative Site, Amsterdam
Novartis Investigative Site, Oslo
Novartis Investigative Site, Gdansk
Novartis Investigative Site, Lodz
Novartis Investigative Site, Poprad
Novartis Investigative Site, Adana
Gazi University Medical Faculty, Ankara
Novartis Investigative Site, Middlesex
Lead Sponsor
Novartis Pharmaceuticals
INDUSTRY